Insight Molecular Diagnostics CSO Achieves 200 Publications, Validates GraftAssure FDA Push
IMDX•Insight Molecular Diagnostics’ Chief Science Officer Ekkehard Schuetz published his 200th scientific article, bolstering the scientific pedigree behind the company’s dd-cfDNA GraftAssure assays. Dr. Schuetz, with an H-index of 58 and over 11,000 citations, co-invented the proprietary testing technology now under FDA review.
1. CSO’s 200th Publication Milestone
Prof. Dr. Ekkehard Schuetz, Chief Science Officer at Insight Molecular Diagnostics, reached a career landmark by publishing his 200th scientific article, placing him in the top 2.5% of 2.6 million researchers globally and the top 2% in laboratory diagnostics. His work has amassed over 11,000 citations and reflects 35 years of molecular diagnostics research.
2. Validation of Core dd-cfDNA Technology
Dr. Schuetz and co-inventor Dr. Julia Beck developed the digital PCR-based dd-cfDNA testing technology that underpins the GraftAssure family of assays, demonstrating superior analytical sensitivity over NGS methods. Key studies include a randomized interventional trial validating dd-cfDNA as a biopsy rule-in test and a head-to-head SNP comparison confirming enhanced assay performance.
3. FDA Submission and Commercial Strategy
Earlier this year, Insight Molecular Diagnostics submitted its GraftAssureDx kit for FDA marketing authorization, aiming to decentralize organ rejection testing by enabling in-house transplant center laboratories to deliver faster, cost-effective results. Successful authorization would position the company to capture a leading share of the dd-cfDNA transplant monitoring market.
